Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Individualizing aspirin therapy for prevention of cardiovascular events.

× No keyword cloud information.

8 in total

1. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.

Authors: E J Wallis; L E Ramsay; I Ul Haq; P Ghahramani; P R Jackson; K Rowland-Yeo; W W Yeo
Journal: BMJ Date: 2000-03-11

2. Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation.

Authors: Jean-Pierre Boissel; Emmanuel Amsallem; Michel Cucherat; Patrice Nony; Margaret C Haugh
Journal: Eur J Clin Pharmacol Date: 2004-09-16 Impact factor: 2.953

3. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.

Authors: T W Meade; P J Brennan
Journal: BMJ Date: 2000-07-01

4. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.

Authors: P S Sanmuganathan; P Ghahramani; P R Jackson; E J Wallis; L E Ramsay
Journal: Heart Date: 2001-03 Impact factor: 5.994

5. Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions.

Authors: Claire Couty; Igor Faddeenkov; Natacha Go; Solène Granjeon-Noriot; Simon Arsène; Daniel Šmít; Riad Kahoul; Ben Illigens; Jean-Pierre Boissel; Aude Chevalier; Lorenz Lehr; Christian Pasquali; Alexander Kulesza
Journal: Nat Commun Date: 2022-04-13 Impact factor: 17.694

Individualizing aspirin therapy for prevention of cardiovascular events.

1. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.

2. Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation.

3. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.

4. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.

5. Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions.

6. Treatment of high blood pressure and gain in event-free life expectancy.

Review 7. Effect model law: an approach for the implementation of personalized medicine.

8. Revisiting the relationship between baseline risk and risk under treatment.